BioCentury | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

...Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving...
...of HPV types 6 and 11. Vaxart Inc. (NASDAQ:VXRT), South San Francisco, Calif. Product: Teslexivir (BTA074...
...area reduction and time to clearance Status: Phase II data Milestone: NA Elizabeth S. Eaton Teslexivir (ap611074, BTA074) Vaxart...
BioCentury | Feb 15, 2016
Clinical News

BTA074: Phase II started

...Biota began a double-blind, placebo-controlled, South American Phase II trial to evaluate topical BTA074 5% gel...
...by HPV types 6 and 11. Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Alpharetta, Ga. Product: BTA074 (formerly AP611074...
BioCentury | Mar 16, 2015
Company News

Anaconda Pharma, Biota Pharmaceuticals deal

...for up to $30 million in clinical and regulatory milestones, plus low single-digit royalties. Anaconda’s AP611074...
BioCentury | Feb 3, 2014
Clinical News

AP611074: Phase IIa data

...A double-blind, placebo-controlled, Phase IIa trial in 24 condyloma patients showed that twice-daily AP611074 5% topical...
...was safe with no patient drop-outs or treatment interruptions reported. Additionally, 13% of patients receiving AP611074...
...clearance of the lesion area. In the per protocol (PP) population, 20% of patients receiving AP611074...
Items per page:
1 - 4 of 4